Navigation Links
New Study Shows Concord Grape Juice has a Heart-Healthy Effect not yet Reported With Red Wine
Date:10/2/2007

CONCORD, Mass., Oct. 2 /PRNewswire/ -- Many studies have suggested that moderate red wine consumption is beneficial to cardiovascular health. But what if you'd like to skip the alcohol? Take heart: laboratory research, just presented at the WINEHEALTH 2007 conference in Bordeaux, France, showed that Concord grape juice stimulated an arterial relaxation effect in a similar fashion to red wine. The French researchers also reported that the Concord grape juice induced a prolonged relaxation effect that has not yet been reported with red wine.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070913/NYTH022LOGO-b )

Dr. Valerie Schini-Kerth and a team of researchers of the Universite Louis Pasteur de Strasbourg, France, found that Concord grape juice stimulated the production of nitric oxide in endothelial cells, providing a vasorelaxation effect. It is known that nitric oxide is important in the body's natural system for maintaining healthy, flexible blood vessels and helps support healthy blood pressure.

Researchers further discovered that Concord grape juice produced this relaxation effect by stimulating the same chemical reactions in the arteries that are activated by red wine. The beneficial effect provided by Concord grape juice lasted up to six hours, whereas this extended effect has not been reported with red wine. This research suggests that the benefits of drinking Concord purple grape juice may last long after finishing the juice.

This research also demonstrates that it's the components of the grape, rather than alcohol, which produce this beneficial effect for the heart.

This study supports other preliminary research in which Concord grape juice had a blood pressure-lowering effect. So, for those looking for an alternative to red wine, grape juice made from Concord grapes provides a delicious, family-friendly, heart-healthy alternative.

Welch Foods Inc. is committed to supporting independent research exploring the role of Concord grape juice in a healthy lifestyle and provided funding and Concord grape juice for this study.


'/>"/>
SOURCE Welch Foods Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... Feb. 8, 2016  HemaFlo Therapeutics, Inc. announced today that ... US Patent Number 9,119,880 covering the use of NephroFlow to ... , PhD, HemaFlo,s founder, said, "We are pleased to secure ... Dale Peterson , PhD, HemaFlo,s founder, said, "We are ... --> Dale Peterson , PhD, HemaFlo,s ...
(Date:2/8/2016)... Feb. 8, 2016  Sangamo BioSciences, Inc. (NASDAQ: ... editing, announced that the U.S. Food and Drug ... Drug (IND) application for SB-318, a single treatment ... Mucopolysaccharidosis Type I (MPS I). The SB-318 IND ... initiate a Phase 1/2 clinical study (SB-318-1502) designed ...
(Date:2/8/2016)... , 8. Februar 2016  LivaNova, ... heute eine Infografik mit dem Titel „Epilepsy ... Welt), mit der der Krankheit gegenüber ein ... dazu ermutigen soll, Medikamentenresistenz bei Epilepsie auf ... allgemeinen Diskussion zu machen. Mithilfe der neuen ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... February 08, 2016 , ... ... Houma, LA, celebrates the beginning of a new charity campaign. As part of ... Appointed Special Advocates (CASA). In the belief that children deserve a voice, and ...
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... If you ... much to handle, you are not alone. According to the Center for Disease Control ... disease, stroke, type 2 diabetes and certain types of cancer, some of the leading ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... program serving the greater Venice, FL area, has initiated a fundraiser for a ... car accident just four days after Christmas. To support this beautiful child who ...
(Date:2/8/2016)... ... February 08, 2016 , ... Eating disorders and post-traumatic ... of women and men with eating disorders report a history of trauma, research ... development of an eating disorder. , At the 2016 iaedp Symposium, the ...
(Date:2/8/2016)... ... February 08, 2016 , ... The Association of ... AHCC and the Home Health and Hospice ICD-10 Transition Workgroup are working closely ... coding guidance and clarifications, to address concerns over the use of 'A' as ...
Breaking Medicine News(10 mins):